GSK (NYSE:GSK) Rating Lowered to Hold at Deutsche Bank Aktiengesellschaft

GSK (NYSE:GSK - Get Free Report) was downgraded by equities research analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating in a research note issued on Friday, MarketBeat.com reports.

GSK has been the topic of a number of other reports. Argus upgraded GSK to a "strong-buy" rating in a report on Wednesday, August 7th. Barclays raised shares of GSK to a "hold" rating in a research note on Tuesday, August 27th. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and cut their price target for the company from $53.00 to $39.50 in a research note on Tuesday. Seven investment analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $43.25.

GSK Stock Down 2.9 %

GSK stock traded down $1.01 during midday trading on Friday, reaching $33.38. The stock had a trading volume of 11,896,558 shares, compared to its average volume of 4,079,172. The company has a fifty day moving average price of $39.29 and a two-hundred day moving average price of $40.75. The company has a market capitalization of $69.18 billion, a P/E ratio of 21.37, a PEG ratio of 1.35 and a beta of 0.66. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK has a 12 month low of $32.83 and a 12 month high of $45.92.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the business's stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares of the company's stock, valued at $134,205,528. This represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 10.00% of the company's stock.

Institutional Trading of GSK

Several hedge funds have recently added to or reduced their stakes in the stock. Taika Capital LP bought a new position in shares of GSK during the 3rd quarter worth $1,028,000. Stifel Financial Corp grew its position in shares of GSK by 9.7% in the third quarter. Stifel Financial Corp now owns 604,973 shares of the pharmaceutical company's stock valued at $24,731,000 after purchasing an additional 53,440 shares in the last quarter. IHT Wealth Management LLC raised its stake in shares of GSK by 49.6% during the 3rd quarter. IHT Wealth Management LLC now owns 24,929 shares of the pharmaceutical company's stock valued at $1,015,000 after purchasing an additional 8,266 shares during the period. Hotchkis & Wiley Capital Management LLC lifted its holdings in GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock worth $144,803,000 after purchasing an additional 833,080 shares in the last quarter. Finally, Hilltop Holdings Inc. purchased a new stake in GSK during the 3rd quarter worth about $331,000. Institutional investors own 15.74% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.